New Study for K-Ras Stage IV : Enroll THIS WEEK!

dianetavegia
Member Posts: 1,942
Click Here for full article
The open-label, 56-patient KRAS-mutated colorectal cancer study is being conducted at three U.S. locations. Patient enrollment begins this week. All subjects will receive Imprime PGG® at 4 mg/kg weekly plus standard doses of Erbitux®. Tumor measurements and determination of tumor responses for this study will be performed according to Response Evaluation Criteria in Solid Tumors (RECIST).
The open-label, 56-patient KRAS-mutated colorectal cancer study is being conducted at three U.S. locations. Patient enrollment begins this week. All subjects will receive Imprime PGG® at 4 mg/kg weekly plus standard doses of Erbitux®. Tumor measurements and determination of tumor responses for this study will be performed according to Response Evaluation Criteria in Solid Tumors (RECIST).
0
Discussion Boards
- 119.8K All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 119.9K Cancer specific
- 2.8K Anal Cancer
- 433 Bladder Cancer
- 300 Bone Cancers
- 1.6K Brain Cancer
- 28.3K Breast Cancer
- 381 Childhood Cancers
- 27.7K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.1K Gynecological Cancers (other than ovarian and uterine)
- 12.7K Head and Neck Cancer
- 6.2K Kidney Cancer
- 649 Leukemia
- 772 Liver Cancer
- 4.1K Lung Cancer
- 5K Lymphoma (Hodgkin and Non-Hodgkin)
- 224 Multiple Myeloma
- 7.1K Ovarian Cancer
- 38 Pancreatic Cancer
- 479 Peritoneal Cancer
- 5.1K Prostate Cancer
- 1.2K Rare and Other Cancers
- 524 Sarcoma
- 698 Skin Cancer
- 638 Stomach Cancer
- 190 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.7K Uterine Cancer
- 6.2K Other Discussion Boards